Study shows education level, income impact access to stem cell transplantation for acute myeloid leukemia patients
Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...
Moleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid Leukemia
(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete ...
The American Journal of Managed Care2h
In Myeloid Neoplasms, Next-Generation Sequencing Can Be Inappropriate—and Money-Wasting
A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...
Tontitown woman leukemia-free after live-saving transplant from sister
Carla Harris has been diagnosed with and beaten acute myeloid leukemia thanks to a bone marrow transplant from her sister, ...
Science Daily6d
Changes in blood cell production over the lifetime could impact leukemia outcomes
The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
- REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - ...
The American Journal of Managed Care1d
Shorter Duration of Venetoclax Possible for Some Patients With Newly Diagnosed AML
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...
Targeted Oncology2d
Uproleselan Misses Primary OS End Point in AML, But May Benefit Subgroups
A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from ...